How Has the Hematocrit Test Devices Market Size Evolved in Recent Years?
The hematocrit test devices market has seen considerable growth due to a variety of factors.
• The hematocrit test devices market has expanded steadily in recent years. It will rise from $4.63 billion in 2024 to $4.95 billion in 2025, at a compound annual growth rate (CAGR) of 6.9%.
The growth is driven by increased awareness of anemia, iron and vitamin deficiencies, the rise in chronic diseases, government funding, and a growing population.
What are the Market Size and Expected Growth Rates for the Hematocrit Test Devices Market?
The hematocrit test devices market is expected to maintain its strong growth trajectory in upcoming years.
• The hematocrit test devices market is projected to grow to $6.37 billion by 2029, at a CAGR of 6.5%.
This growth is attributed to the rising prevalence of anemia, blood disorders, an aging population, a growing focus on health and fitness, and the increasing demand for cardiovascular diagnostic equipment. Trends include cutting-edge solutions, advancements in medical technology, the development of efficient and innovative hematocrit testing products, and improvements in healthcare.
Which Key Drivers Are Propelling The Hematocrit Test Devices Market's Growth?
The rising incidence of blood disorders is anticipated to drive the growth of the hematocrit test devices market. Blood disorders affect various components of blood, such as red and white blood cells, platelets, and plasma. These conditions are becoming more widespread due to factors like genetic factors, environmental pollution, and lifestyle changes. Hematocrit test devices are used to measure the percentage of red blood cells in blood, offering important insights into a patient’s hematological health. For example, the American Cancer Society forecasts approximately 62,770 new leukemia cases and 23,670 deaths in the U.S. in 2024, with a significant number of acute myeloid leukemia (AML) cases, especially in adults. This surge in blood disorders is boosting the hematocrit test device market.
What Are The Key Segments Within The Global Hematocrit Test Devices Market?
The hematocrit test devices market covered in this report is segmented –
1) By Product: Hematocrit Test Meter, Hematocrit Test Analyzer, Reagents And Consumables
2) By Application: Anemia, Polycythemia Vera, Congenital Heart Diseases, Other Applications
3) By End-User: Hospitals And Ambulatory Surgical Centers, Clinics, Diagnostic And Pathology Labs, Other End-Users
Subsegments:
1) By Hematocrit Test Meter: Handheld Hematocrit Meters, Portable Hematocrit Meters, Desktop Hematocrit Meters, Point-Of-Care Hematocrit Meters, Digital Hematocrit Meters, Battery-Powered Hematocrit Meters
2) By Hematocrit Test Analyzer: Automated Hematocrit Analyzers, Benchtop Hematocrit Analyzers, Semi-Automated Hematocrit Analyzers, Microhematocrit Analyzers, High-Throughput Hematocrit Analyzers, Compact Hematocrit Analyzers
3) By Reagents And Consumables: Hematocrit Test Strips, Hematocrit Pipettes And Capillaries, Blood Sample Collection Tubes For Hematocrit Testing, Quality Control Reagents For Hematocrit Testing, Calibration Standards For Hematocrit Devices, Disposable Test Kits And Consumables
Pre-Book The Hematocrit Test Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Hematocrit Test Devices Industry?
Leading firms in the hematocrit test device market are devising innovative offerings, such as complete blood count (CBC) hematology analyzers, aimed at delivering both quantitative and qualitative data about blood cells. A CBC hematology analyzer is a mechanized tool used for examining and quantitating different components of blood including red blood cells(RBCs), white blood cells(WBCs), and platelets. An illustration of this is seen in March 2022 when Mindray Medical International Limited, a firm based in China specializing in medical devices, unveiled the BC-700 hematology analyzer series. This is a CBC hematology analyzer that integrates both CBC and erythrocyte sedimentation rate (ESR) tests. The BC-700 hematology analyzer and its equivalent BC-720, BC-760, and BC-780 form a series designed to equip medium-volume laboratories with the sophisticated diagnostic technologies typically seen in premium products. The BC-700 Series, being a smaller version of the elite BC-6000 Series, is constructed on the same platform and features Mindray's SF Cube 3D analysis technology. The SF Cube technology employs fluorescence and bi-angular laser scatter signals to evaluate target cells in tri-dimensional space.
Who Are the Key Players In The Hematocrit Test Devices Market?
Major companies operating in the hematocrit test devices market are:
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bayer AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Siemens Healthcare GmbH
• Becton
• Dickinson and Company (BD)
• Terumo Corporation
• Beckman Coulter Inc.
• Mindray Medical International Limited
• bioMérieux SA
• Sysmex Corporation
• Horiba Ltd.
• Nihon Kohden Corporation
• Erba Mannheim
• Heska Corporation
• EKF Diagnostics Holding Plc.
• Nova Biomedical Corporation
• Boule Diagnostics AB
• Stanbio Laboratory Lp
• Drucker Diagnostics
• A. Menarini Diagnostics Srl
• Sensa Core
• Mikroscan Technologies Inc.
What Are The Regional Insights Into The Hematocrit Test Devices Market?
North America was the largest region in the hematocrit test devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
